Loading company
Faeth Therapeutics, Inc.
FTH · Nasdaq · ·
$28.11+1.6%Sep 29 close
- 1M
- -16.9%
- 6M
- +11.9%
- 1Y
- +197.5%
- 5Y
- -86.6%
FTH · Nasdaq · ·
$28.11+1.6%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$16M | -$4.9M | -224.29% |
| Profit per share | -$2.84 | -$3.91 | +27.37% |
| Free Cash Flow | -$15.7M | -$5.9M | -164.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Faeth Therapeutics, Inc. has no earnings call transcript available.
“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated in the second half of 2026. PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Faeth Therapeutics, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.